FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766581537> ?p ?o ?g. }

• W2766581537 endingPage "13" @default.
• W2766581537 startingPage "7" @default.
• W2766581537 abstract "Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. Methods In this phase II, open-label trial, patients with predefined BRAF V600E–mutated malignancies received dabrafenib 150 mg twice daily and trametinib 2 mg once daily until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed overall response rate. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Results Sixteen patients with BRAF V600E–mutated anaplastic thyroid cancer were evaluable (median follow-up, 47 weeks; range, 4 to 120 weeks). All patients had received prior radiation treatment and/or surgery, and six had received prior systemic therapy. The confirmed overall response rate was 69% (11 of 16; 95% CI, 41% to 89%), with seven ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached as a result of a lack of events, with 12-month estimates of 90%, 79%, and 80%, respectively. The safety population was composed of 100 patients who were enrolled with seven rare tumor histologies. Common adverse events were fatigue (38%), pyrexia (37%), and nausea (35%). No new safety signals were detected. Conclusion Dabrafenib plus trametinib is the first regimen demonstrated to have robust clinical activity in BRAF V600E–mutated anaplastic thyroid cancer and was well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease." @default.
• W2766581537 created "2017-11-10" @default.
• W2766581537 creator A5000418012 @default.
• W2766581537 creator A5019473289 @default.
• W2766581537 creator A5021656597 @default.
• W2766581537 creator A5025737516 @default.
• W2766581537 creator A5030914311 @default.
• W2766581537 creator A5040437590 @default.
• W2766581537 creator A5043675371 @default.
• W2766581537 creator A5051301531 @default.
• W2766581537 creator A5054394647 @default.
• W2766581537 creator A5077961608 @default.
• W2766581537 creator A5080295544 @default.
• W2766581537 creator A5084791255 @default.
• W2766581537 creator A5085625313 @default.
• W2766581537 creator A5086245221 @default.
• W2766581537 date "2018-01-01" @default.
• W2766581537 modified "2023-10-11" @default.
• W2766581537 title "Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer" @default.
• W2766581537 cites W1846586690 @default.
• W2766581537 cites W1971381075 @default.
• W2766581537 cites W1977731422 @default.
• W2766581537 cites W1995223428 @default.
• W2766581537 cites W1998915601 @default.
• W2766581537 cites W2033980810 @default.
• W2766581537 cites W2076668534 @default.
• W2766581537 cites W2084929142 @default.
• W2766581537 cites W2096387850 @default.
• W2766581537 cites W2103557568 @default.
• W2766581537 cites W2109994599 @default.
• W2766581537 cites W2112400388 @default.
• W2766581537 cites W2120775347 @default.
• W2766581537 cites W2139248078 @default.
• W2766581537 cites W2146737519 @default.
• W2766581537 cites W2147387301 @default.
• W2766581537 cites W2156078931 @default.
• W2766581537 cites W2162643152 @default.
• W2766581537 cites W2176310149 @default.
• W2766581537 cites W2279570938 @default.
• W2766581537 cites W2344901527 @default.
• W2766581537 cites W2409383155 @default.
• W2766581537 cites W2463603441 @default.
• W2766581537 cites W2471247568 @default.
• W2766581537 cites W2544712280 @default.
• W2766581537 cites W2570525228 @default.
• W2766581537 cites W2611270905 @default.
• W2766581537 cites W2614470022 @default.
• W2766581537 cites W3164126191 @default.
• W2766581537 doi "https://doi.org/10.1200/jco.2017.73.6785" @default.
• W2766581537 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5791845" @default.
• W2766581537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29072975" @default.
• W2766581537 hasPublicationYear "2018" @default.
• W2766581537 type Work @default.
• W2766581537 sameAs 2766581537 @default.
• W2766581537 citedByCount "559" @default.
• W2766581537 countsByYear W27665815372017 @default.
• W2766581537 countsByYear W27665815372018 @default.
• W2766581537 countsByYear W27665815372019 @default.
• W2766581537 countsByYear W27665815372020 @default.
• W2766581537 countsByYear W27665815372021 @default.
• W2766581537 countsByYear W27665815372022 @default.
• W2766581537 countsByYear W27665815372023 @default.
• W2766581537 crossrefType "journal-article" @default.
• W2766581537 hasAuthorship W2766581537A5000418012 @default.
• W2766581537 hasAuthorship W2766581537A5019473289 @default.
• W2766581537 hasAuthorship W2766581537A5021656597 @default.
• W2766581537 hasAuthorship W2766581537A5025737516 @default.
• W2766581537 hasAuthorship W2766581537A5030914311 @default.
• W2766581537 hasAuthorship W2766581537A5040437590 @default.
• W2766581537 hasAuthorship W2766581537A5043675371 @default.
• W2766581537 hasAuthorship W2766581537A5051301531 @default.
• W2766581537 hasAuthorship W2766581537A5054394647 @default.
• W2766581537 hasAuthorship W2766581537A5077961608 @default.
• W2766581537 hasAuthorship W2766581537A5080295544 @default.
• W2766581537 hasAuthorship W2766581537A5084791255 @default.
• W2766581537 hasAuthorship W2766581537A5085625313 @default.
• W2766581537 hasAuthorship W2766581537A5086245221 @default.
• W2766581537 hasBestOaLocation W27665815372 @default.
• W2766581537 hasConcept C121608353 @default.
• W2766581537 hasConcept C126322002 @default.
• W2766581537 hasConcept C143998085 @default.
• W2766581537 hasConcept C184235292 @default.
• W2766581537 hasConcept C197934379 @default.
• W2766581537 hasConcept C203092338 @default.
• W2766581537 hasConcept C2776131300 @default.
• W2766581537 hasConcept C2776694085 @default.
• W2766581537 hasConcept C2778472372 @default.
• W2766581537 hasConcept C2778830669 @default.
• W2766581537 hasConcept C2779761222 @default.
• W2766581537 hasConcept C2780256643 @default.
• W2766581537 hasConcept C2780739268 @default.
• W2766581537 hasConcept C2781249067 @default.
• W2766581537 hasConcept C2781413609 @default.
• W2766581537 hasConcept C2908647359 @default.
• W2766581537 hasConcept C2994587330 @default.
• W2766581537 hasConcept C535046627 @default.
• W2766581537 hasConcept C57074206 @default.
• W2766581537 hasConcept C71924100 @default.

• next